Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease  by MacMillan, Margaret L et al.
40
INTRODUCTION
Acute graft-versus-host disease (GVHD) remains a
signiﬁcant cause of morbidity and mortality after allogeneic
hematopoietic stem cell transplantation (HSCT). High-dose
steroids for acute GVHD induce a durable remission in
50% of cases [1-6]. For those patients who do not achieve
remission, a variety of second-line therapies have been used
with success in approximately 10% to 30% of cases [2,4,7-
10]. Administration of antithymocyte globulin (ATG) as sec-
ond-line therapy has been studied in HSCT recipients in
the 1970s and 1980s, and responses were demonstrated in
20% to 50% of patients with steroid-resistant acute GVHD
[4,7,8]. Over the past decade, the nature of HSCT has
changed substantially with the increased use of alternate
donor sources, changes in GVHD prophylaxis, and support-
ive care. There have been few reports addressing the use of
ATG in recent patients.
To assess the impact of ATG on steroid-resistant acute
GVHD in the 1990s, we retrospectively analyzed the clini-
cal response and survival of 79 HSCT patients, uniformly
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ABSTRACT
Second-line therapies for steroid-resistant acute GVHD have been used with limited success. We have reviewed the
responses of 79 hematopoetic stem cell transplant (HSCT) patients uniformly treated from 1990-1998 with equine
antithymocyte globulin (ATG) for steroid-resistant acute GVHD, defined as progression of acute GVHD after 4 days
of treatment with prednisone or no improvement of acute GVHD after 7 days of treatment with prednisone. Patients
received HSCT from 34 related (32 matched sibling/2 partially matched) and 45 unrelated (14 HLA-A, -B, -DRB1
matched/31 partially matched) donors. Prior to ATG therapy, severe (grade III-IV) GVHD was observed in 34 patients
(43%). Organs involved included skin in 81% of patients, lower GI tract in 52%, upper GI tract in 28%, and liver in
11%. Treatment consisted of 1-5 courses (median, 2 courses) of ATG (15 mg/kg per dose bid × 5 days) given for a
median of 16 days (range, 5 to 44 days) after the onset of GVHD. All patients continued to receive prednisone,
60 mg/m2 per day (or methylprednisolone IV equivalent), plus CSA (75%) or tacrolimus (4%). At day 28 of treatment,
overall improvement was observed in 54% of patients; durable (≥28 days) complete response was observed in 20% of
patients, and partial response was observed in 34% of patients. In multivariate analysis, patients with CML or a malig-
nant disease other than acute leukemia had a greater likelihood of overall response than did those with nonmalignant
diseases. Patients with acute skin GVHD (with or without other organ involvement) responded most frequently.
Chronic GVHD developed in 51% of patients by 1 year after HSCT. One patient developed EBV lymphoproliferative
disease. For the entire cohort, the probability of survival at 1 year was 32% (95% CI, 22%-42%). In multivariate analy-
sis, factors associated with better survival included earlier onset of acute GVHD, shorter time from initial treatment
for GVHD to treatment with ATG, and the use of non–T-cell–depleted stem cell grafts. These data suggest that treat-
ment with ATG can be an active therapy, especially in patients with skin GVHD and early signs of steroid resistance.
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treated at a single institution from 1990 to 1998 on protocol
with equine ATG (15 mg/kg per dose bid × 5 days) for
steroid-resistant acute GVHD.
PATIENT POPULATION AND METHODS
Patients
Clinical and laboratory data were retrieved from the
University of Minnesota Bone Marrow Transplant Database,
which systematically and prospectively collects data on all
consecutive HSCT patients at our institution. From August
1990 to November 1998, 1016 patients received allogeneic
HSCTs at the University of Minnesota. All protocols for
transplantation and treatment of GVHD were reviewed and
approved by the Institutional Review Board at the University
of Minnesota. All patients and/or parents of patients gave
informed consent. Of the 1016 patients, 645 (63%) devel-
oped acute GVHD, and 202 received secondary immuno-
suppressive therapy for steroid-resistant acute GVHD. Of
these 202 patients, 97 were enrolled in a randomized trial of
ATG as initial therapy for GVHD [6], and a subset of 79
allogeneic HSCT recipients, who developed steroid-resistant
acute GHVD and who did not receive ATG as initial ther-
apy, were enrolled in this study.
Patient characteristics, including underlying disease,
type of donor, and type of GVHD prophylaxis are shown in
Table 1. Patients received their HSCTs from August 1990
to November 1998 and were followed for a median of
6 years (range, 1.0-9.0 years). HSCT sources included bone
marrow (BM; n = 73), peripheral blood stem cells (PBSC;
n = 4), and umbilical cord blood (UCB; n = 2). Details of
the preparative therapy and GVHD prophylaxis that were
used, as well as supportive therapy techniques, have been
previously reported [11,12]. Eighty-four percent of patients
received total body irradiation (TBI)-based regimens and
16% of patients received chemotherapy-alone regimens.
GVHD prophylaxis consisted of cyclosporin A (CSA)-based
therapy for 67% of patients, T-cell depletion for 13% of
patients, methotrexate-based therapy (no CSA) for 18% of
patients, and tacrolimus for 2% of patients. Patients with
T cell–depleted grafts were older, with a median age of
34 years (range, 10-52 years) compared to patients with
unmanipulated grafts with a median age of 24 years (range,
0.4-52 years).
Diagnosis and Staging of GVHD
Acute GVHD was diagnosed clinically with histological
conﬁrmation whenever possible. Symptoms of acute GVHD
were graded by standard clinical criteria [3,13], modiﬁed to
include upper gastrointestinal (GI) acute GVHD per the
GVHD consensus conference [14,15], and by the IBMTR
severity index [16]. Grade of GVHD refers to clinical (not
histologic) grade throughout this report. Initial score was
deﬁned as the maximum stage in each organ during a 15-day
window (day –10 to day 5) around the initiation of ATG
therapy. Real-time staging of each organ was determined by
the attending physician, supported by laboratory and clinical
information abstracted from the medical records. The overall
grade was determined by a computer algorithm, incorporat-
ing all available clinical GVHD organ staging data, centrally
reviewed by the GVHD Grading Committee at our center
(S.M.D. and D.J.W.), and prospectively recorded in the
University of Minnesota BMT Database.
Therapy for GVHD
Primary treatment of acute GVHD consisted of daily
divided-dose prednisone, 60 mg/m2 PO (or methylpred-
nisolone IV equivalent, 48 mg/m2), plus CSA in 53 patients
(67%) or tacrolimus in 2 patients (3%). In addition, patients
with acute skin GVHD were treated with topical 0.1% tri-
amcinolone cream or 1% hydrocortisone cream (for facial
rash) tid. Steroid-resistant acute GVHD was deﬁned as pro-
gression of acute GVHD after 4 days of treatment with
prednisone or no improvement of acute GVHD after 7 days
of treatment with prednisone. Patients with limited skin
(grade I) acute GVHD were eligible for this study if they
failed to improve after 7 to 14 days of prednisone therapy.
For steroid-resistant acute GVHD, all patients received
equine ATG (ATGAM; Pharmacia, Peapack, NJ), 15 mg/kg
per dose IV over 3 hours bid for 5 days for a total of 10 doses.
Premedications consisted of acetaminophen and diphenhy-
dramine. Prednisone 30 mg/m2 PO (or methylprednisolone
IV equivalent, 24 mg/m2) was given with each dose of
ATG and then continued for at least 7 days. Patients with
acute skin GVHD continued to receive treatment with
Table 1. Clinical Features of Patients with Acute GVHD Treated With ATG*
Features n (%)
Male:female ratio 50:29 (63:37)
Male donor/male recipient 34 (43)
Male donor/female recipient 16 (20)
Female donor/male recipient 16 (20)
Female donor/female recipient 13 (17)






Other malignancy 2 (2)
Metabolic disorder 7 (9)
Aplastic anemia/bone marrow failure 5 (6)
Immune deficiency 2 (3)
Donor type
Matched related 32 (41)
Mismatched related 2 (3)
Matched unrelated 14 (18)
Mismatched unrelated 31 (39)
Preparative therapy
Cyclophosphamide and TBI 56 (71)
TBI with other chemotherapy 10 (13)
Chemotherapy alone 10 (13)
Chemotherapy and ATG 3 (4)
GVHD prophylaxis
CSA/MTX 46 (58)
CSA/prednisone ± other 7 (9)
MTX/ATG/prednisone 10 (13)
Ex vivo T-lymphocyte depletion 10 (13)
Tacrolimus 2 (3)
MTX alone 4 (5)
*MDS indicates myelodysplastic syndrome.
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0.1% triamcinolone cream to the body and 1% hydrocorti-
sone cream to the face. If a response to ATG was observed,
patients continued therapy with single-dose prednisone,
60 mg/m2 per day PO, for 7 days and then commenced a
taper of steroids over 8 weeks [15]. If no response to ATG
was observed after 7 to 10 days, or progression of GVHD
occurred after 14 days, the ATG course was repeated.
Patients received supportive care, which included ongo-
ing prophylaxis for bacterial infections (250 mg penicillin V
potassium PO, bid), fungal infections (clotrimazole, nys-
tatin, or fluconazole), Pneumocystis carinii pneumonia
(trimethoprim-sulfa, double strength bid every Monday and
Tuesday), and cytomegalovirus (CMV) (800 mg acyclovir
PO 5 times per day). Children received the same prophy-
laxis appropriately dose-adjusted for weight.
At initiation of ATG treatment, overall GVHD grade
was grade I in 7 patients (9%), grade II in 38 patients (48%),
grade III in 30 patients (38%), and grade IV in 4 patients
(5%). The 7 patients with overall grade I GHVD had
steroid-resistant stage II skin GVHD, which failed to
improve after 7 to 28 days of prednisone therapy. Maximum
initial GVHD stage in each organ for each patient is shown
in Table 2. Median time to onset of GVHD from day of
HSCT was 28 days (range, 8-91 days). Median time to treat-
ment with ATG after initiation of initial steroid therapy was
16 days (range, 5-79 days). Median time to treatment with
ATG from day of HSCT was 48 days (range, 15-105 days).
The total number of courses of ATG treatment was 1 for
31 patients (39%), 2 for 29 patients (37%), 3 for 9 patients
(11%), 4 for 6 patients (8%), and 5 for 4 patients (5%).
Measurement of GVHD Response to ATG
Administration
The day 28 response was determined from the maxi-
mum acute GVHD grade observed 28 days (±14 days) after
the ﬁrst course of ATG treatment was initiated. Response to
therapy was evaluated by the attending physician of the
transplantation service and prospectively recorded in the
University of Minnesota BMT Database at treatment days
7, 14, 21, 28, and 42 by determining the GVHD clinical
stage score for each time point (±3 days) [5]. Complete
response (CR) was deﬁned as the complete resolution of all
acute GVHD symptomatology in all organs. To be consid-
ered a CR, this score had to be maintained for 28 days (ie,
beyond day 56 after initiating ATG therapy) without the
patient receiving additional treatment. Partial response (PR)
was defined as durable (≥28 further days) improvement in
GVHD stage in all initial GVHD target organs, without
complete resolution and without worsening in any other
GVHD target organs. No response (NR) was deﬁned as the
same grade of GVHD or progression of GVHD in any
organ, or death before day 28 after ATG. Patients who
received additional ATG courses or a second salvage regi-
men were considered nonresponders. Progression was
deﬁned as worsening GVHD in ≥1 organ with or without
amelioration in any organ. For assessment of treatment
response, a GVHD-stage score was determined for each
patient, as previously described [2]. This stage score repre-
sented the sum of each acute GVHD organ stage (0 to 4)
plus 1 point for upper GI involvement and thus had a maxi-
mum possible score of 13.
Statistical Analysis
The major end points of this study were response to
GVHD therapy at day 28 after treatment, and survival. Sta-
tistical analysis of response to therapy was performed using
Pearson’s chi-square test. The independent effect of study
variables on response was determined using multivariate
logistic regression [17].
Survival was measured from the time of initiation of ATG
therapy. The Kaplan-Meier method was used to estimate sur-
vival with 95% conﬁdence intervals [CIs] derived from stan-
dard errors. Comparison within study cohorts was completed
by the log-rank statistic. Cox regression was used to deter-
mine the independent effect of these factors [18]. Cumulative
incidence curves were calculated to estimate the incidences of
chronic GVHD and infectious complications. Deaths from
other causes were treated as competing risks [19].
Study variables included age, year of transplantation,
sex, sex match, diagnosis, type of donor (related, matched
unrelated, mismatched unrelated), CMV serostatus of the
patient and donor, GVHD prophylaxis regimen, condition-
ing regimen, initial grade of acute GVHD, time to onset of
acute GVHD, time to therapy, and type of organ involve-
ment. The effect of response to therapy on survival was also
investigated as a time-dependent covariate. P values were
not adjusted for multiple comparisons, so nominally statisti-
cally signiﬁcant results should be interpreted with caution.
RESULTS
Response
Of the 79 patients treated with ATG, overall durable
improvement (CR + PR) was observed in 43 patients (54%) by
day 28 after initiation of ATG. CR was achieved in 16 patients
(20%), PR in 27 patients (34%), and NR in 33 patients (42%),
and 3 patients (4%) were unevaluable due to early death.
Various patient characteristics and transplantation con-
ditions were analyzed for their association with clinical
response to ATG therapy by day 28. In univariate analysis,
only a nonmalignant diagnosis was associated with a statisti-
cally signiﬁcant lower likelihood of CR/PR (P = .04). CR or
PR was achieved in 21 of the 34 related donor recipients
(62%; 95% CI, 46%-78%) compared to 22 of 45 unrelated
donor recipients (48%; 95% CI, 33%-63%) (P = .26). CR or
PR was achieved in 39 of 66 patients conditioned with TBI
(59%; 95% CI, 47%-71%) compared with 4 of 13 patients
conditioned with non-TBI preparative therapy (31%; 95%
CI, 6%-56%) (P = .06). There was no association between
CR/PR following ATG treatment and patient age, sex, sex
Table 2. Maximum Initial GVHD Stage at the Onset of ATG Therapy*
0 1 2 3 4
Skin 15 (19%) 8 (10%) 13 (17%) 42 (53%) 1 (1%)
Liver 70 (89%) 1 (1%) 3 (4%) 3 (4%) 2 (3%)
Rectal 38 (48%) 13 (17%) 8 (10%) 17 (22%) 3 (4%)
Upper GI 57 (72%) 22 (28%)
*Data are n (%). Maximum stage during a 15-day window (day –10
to day 5) around the initiation of ATG therapy. 
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match, year of transplantation, CMV serostatus, GVHD
prophylaxis, or time between ﬁrst-line therapy with steroids
and initiation of ATG treatment. In addition, CR/PR to
ATG was not associated with the initial grade of GVHD,
regardless of which scoring system was used [14,16].
The response to ATG treatment among patients with
various combinations of organ involvement was analyzed.
Patients with acute skin GHVD (with or without other
organ involvement) responded most frequently. Of the
64 patients with skin involvement, 39 patients (61%)
achieved CR/PR versus 4 of 15 patients (27%) without skin
involvement (P = .02). Response rates did not differ between
patients with only skin involvement and patients with skin
plus other organ involvement. The number of organs
involved and stage of organ involvement were not prognos-
tic indicators of response to ATG. In addition, organ score
was not predictive of response to GVHD treatment.
The clinical factors relevant to the likelihood of achiev-
ing CR/PR were examined in a multivariate analysis (Table 3).
A diagnosis of chronic myelogenous leukemia (CML) or a
malignant disease other than acute leukemia was associated
with a greater likelihood of CR/PR, compared to a diagnosis
of nonmalignant disease. In addition, patients who had acute
GVHD skin involvement were signiﬁcantly more likely to
respond to ATG therapy than were those without skin
involvement. Type of donor, initial GVHD grade, and time
from steroid therapy to ATG initiation were not signiﬁcant
predictors of response to ATG.
Chronic GVHD
Forty of the 79 patients developed chronic GVHD by
1 year after HSCT, resulting in a cumulative incidence of
53% (95% CI, 39%-67%). By 1 year, 41% of patients had
died from causes other than chronic GVHD (95% CI, 31%-
51%). Chronic GVHD developed in 4 of the 7 patients with
initial grade I GVHD (57%; 95% CI, 24%-90%), 20 of the
38 patients with initial grade II GVHD (53%; 95% CI,
33%-73%), 14 of 30 patients with initial grade III GVHD
(47%; 95% CI, 26%-68%), and 2 of 4 patients with grade
IV GVHD (50%; 95% CI, 1%-99%) (P = not significant
[NS]). Eight of 16 patients who had CR to ATG later devel-
oped chronic GVHD (50%; 95% CI, 22%-78%), 14 of 27
who had PR later developed chronic GVHD (52%; 95%
CI, 30%-74%), and 18 of 33 who had NR later developed
chronic GVHD (55%; 95% CI, 35%-75%) (P = NS).
Infectious Complications
Within the ﬁrst 100 days after transplantation, 29 patients
developed bacterial infections (37%; 95% CI, 26%-48%),
from which 2 died; 14 developed fungal infections (18%;
95% CI, 10%-26%), from which 6 died; and 8 developed
CMV infections (10%; 95% CI, 4%-16%), from which
none died. Only 1 patient developed Epstein-Barr virus
(EBV) lymphoproliferative disease after ATG therapy.
Survival
In the entire cohort of 79 patients, 25 are alive between
1 and 9 years after treatment, with a Kaplan-Meier projected
estimate of 32% survival at 1 year (95% CI, 22%-42%). Vari-
ous clinical factors were examined for their association with
improved survival (Table 4). The probability of survival
Table 3. Factors Associated With Complete/Partial Response to ATG for
Acute GVHD: Multivariate Logistic-Regression Analysis
Factor Odds Ratio of Response (95% CI) P
Diagnosis
Nonmalignancy 1.0
Acute leukemia 2.3 (0.6-9.4) .26
CML 5.7 (1.3-24.2) .02
Other malignancy* 8.6 (1.2-64.2) .04
Skin Involvement
No 1.0
Yes 4.4 (1.2-16.5) .03
*Other malignancy indicates MDS (n = 7), juvenile myelomonocytic
leukemia (n = 1), or non-Hodgkin’s lymphoma (n = 1).
Table 4. Clinical Risk Factors Associated With Survival
No. of Patients
n Who Died 1 year* P†
Overall 79 54 32%
Age
<18 y 34 21 38% .16
≥18 y 45 33 21%
Diagnosis
Acute leukemia 28 18 36% .63
CML 28 20 29%
Other malignancy 9 7 22%
Nonmalignant 14 9 36%
Type of HSCT
Related donor 34 22 35% .10
Matched URD 14 12 14%
Mismatched URD 31 20 35%
GVHD prophylaxis
MTX-containing 14 8 43% .11
CSA-containing 53 35 34%
T-cell depletion 10 9 10%
Conditioning Prep
TBI 66 47 29% .23
Non-TBI 13 7 46%
Initial overall GVHD
1 7 5 29% .29
2 38 22 42%
3-4 34 27 21%
Skin involvement
No 15 13 13% .12
Yes 64 41 36%
Time to onset of GVHD
<4 wk 44 28 36% .24
≥4 wk 35 26 26%
Time between steroids/ATG
≤2 wk 37 20 46% .05
>2 wk 42 34 19%
Response to ATG
CR 16 10 38% .54
PR 27 17 37%
NR 33 24 27%
Overall response to ATG
CR, PR 43 27 37% .27
NR 33 24 27%
*1-year survival from initiation of ATG therapy.
†P values reflect log-rank statistical comparison of survival up to
1 year after initiation of ATG therapy.
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12 months after ATG was similar in related and unrelated
donor recipients, 35% (95% CI, 19%-51%) and 29% (95%
CI, 16%-42%), respectively (P = .58).
Recipients of T cell–replete grafts had a higher proba-
bility of survival at 1 year (36% [95% CI, 25%-47%]) than
did recipients of T cell–depleted grafts at 1 year (10% [95%
CI, 0%-28%]) (P = .04). Other clinical factors, including age
and sex of recipient, year of transplantation, underlying
diagnosis, preparative therapy, or CMV serostatus, had no
association with improved survival.
Using either GVHD scoring system, initial overall
GVHD grade was not associated with improved survival.
With the GVHD consensus conference scoring system [14],
probability of survival at 1 year after ATG therapy for
patients with grade I-II GVHD and grade III-IV GVHD
was 40% (95% CI, 26%-54%) and 21% (95% CI, 8%-34%)
(P = .14), respectively. In addition, the number of organs
involved was not a prognostic factor, with the probability of
survival in patients with 1, 2, or >2 involved organs being
33%, 33%, and 23%, respectively (P = NS). GVHD-stage
score was also not predictive of survival.
Patients in whom ATG therapy was initiated within
2 weeks of steroid treatment had a higher probability of
survival than did patients with a longer period between
treatment regimens (46% [95% CI, 30%-62%] versus 19%
[95% CI, 7%-31%]; P = .05) (Figure 1). No association was
observed between number of ATG courses and survival.
Probability of 1-year survival for patients who received
1 course of ATG was 42% (95% CI, 13%-59%) and 25%
(95% CI, 13%-37%) for patients who received 2 or more
courses (P = .26).
Perhaps surprisingly, achievement of CR by day 28
(±14 days) did not predict improved survival. Probability
of survival at 1 year was 38% (95% CI, 14%-62%) for the
16 patients with CR and 32% (95% CI, 20%-44%) for the
60 patients with PR or NR (P = .73). Similarly, survival
was not affected by overall response (CR + PR). The
probability of the 43 patients with overall response surviv-
ing at 1 year after ATG therapy was 37% (95% CI,
23%-51%) compared to 27% (95% CI, 12%-42%) for
nonresponders (P = .27).
In a multivariate analysis, the use of a non–T cell– depleted
stem cell graft (ie, unmanipulated BM, PBSC, or UCB),
shorter time from transplantation to onset of acute GVHD,
and shorter time from initial steroid treatment to ATG were
independently associated with greater survival (Table 5).
Causes of Death
The primary cause of death was GVHD in 48 patients
(89%) and relapse in 6 patients (11%). Infections were a
contributing cause in 36 deaths (67%).
DISCUSSION
Successful treatment of steroid-resistant acute GVHD is
difﬁcult. In this report, we observed an overall improvement
in 54% of patients receiving ATG for steroid-resistant acute
GVHD and a durable CR in 20% of patients. This outcome
is better than those reported in 2 previous series examining
the role of ATG in steroid-resistant acute GVHD. The
Seattle group reported on a large series of patients who
received secondary treatment for acute GVHD, including
94 patients who received ATG. Of the 79 evaluable patients,
CR was observed in 8% of patients and CR + PR in 30% of
patients [7]. Recently, Khoury et al. reported 58 patients
with steroid-resistant acute GVHD treated with ATG [20].
Of the 52 evaluable patients, CR was observed in 8% of
patients and CR + PR in 31% of patients. In the Khoury
series, the poorer outcome may be due in part to the large
percentage of patients (94%) with severe GVHD (IBMTR
C and D). In our present series, 43% of patients had severe
GVHD (grade III-IV). In addition, the durability of
responses to ATG was not clarified in the earlier series.
Our results are consistent with reports on the use of other
second-line agents for acute GVHD, including steroids and
monoclonal antibodies [2,7,9,10]. Interestingly, our results
are similar to those observed when ATG is used as primary
therapy for acute GVHD [6,8,21].
Response to ATG therapy was observed most often in
patients with skin GVHD and early recognition of steroid
resistance, suggesting that these steroid-resistant patients
benefited the most from ATG therapy. Consistent with
other studies, patient age [2,4,8], sex [2], type of donor
[4,7,8], or GVHD prophylaxis [2,4,7] were not associated
with response to ATG. Other studies have demonstrated
poorer response rates in those patients with more severe
grades of steroid-resistant GVHD [7,8].
In contrast with the current series, we have previously
observed favorable survival in association with a response to
Probability of survival stratiﬁed by time to initiation of ATG therapy.
Table 5. Clinical Factors Associated With Mortality in Acute GVHD: 
Multivariate Analysis
Relative Risk
Favorable Factor of Death (95% CI) P
Prophylaxis for GVHD 
No T-cell depletion 1.0 .03




Time to acute GVHD (per wk) 1.2 (1.0-1.4) .05
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second-line acute GVHD treatment. Weisdorf et al.
reported CR in 7 of 61 matched sibling–donor (MSD)
recipients treated with second-line immunosuppressive
therapy for acute GVHD [2]. Five-year probability of sur-
vival was 23%, and a CR of acute GVHD was an important
predictor of survival [2]. Similarly, Roy et al. observed a
21% CR in 42 recipients of unrelated-donor (URD) trans-
plants, treated with ATG as secondary therapy. Complete
and continuing response to therapy was associated with a
better survival [4]. In the current series, 60% of patients
were recipients of alternate donor stem cells (ie, other than
MSD) [4]. Notably, their response to ATG and their sur-
vival was similar to the MSD recipients.
We identified few demographic or clinical factors that
influenced survival. A longer time from transplantation to
the onset of acute GVHD and a longer time from initial
steroid treatment to ATG therapy were each independently
associated with greater mortality. Because the grade of acute
GVHD did not vary with posttransplantation time, this
factor did not reflect delay in recognition or treatment of
steroid-resistant GVHD.
Over the last 2 decades, studies of supplemental
immunosuppression for steroid-resistant acute GVHD have
included ATG [9,21], tacrolimus [22], anti-cytokines (inter-
leukin [IL]-1RA [23], anti–IL-2R [24-26], and anti–tumor
necrosis factor [27]), anti–T-cell antibodies [9,28-31], or
immunotoxins (XOMA [32,33] and daclizumab [10]) with
varying but only modest response and usually poor survival.
Although ATG is an active agent, improvements in control
of GVHD and survival await more effective reagents. Better
control of the initial manifestations of acute GVHD would
limit the hazards patients face from ongoing GVHD and
long-term immunosuppression.
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